Thymopentin Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Thymopentin evidence and protocol review

Thymic & Immune Research peptide Lyophilized verified

Also known as: TP-5, Thymopoietin II fragment

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

5 mg, 10 mg

Calculator

Preset available

Storage

Lyophilized: store at -20 deg C. After reconstitution: refrigerate 2-8 deg C; verify beyond-use timing against source COA.

Solubility

Highly water-soluble; lyophilized form reconstitutes easily

Catalog Description

Thymopentin is a synthetic pentapeptide corresponding to the active fragment (residues 32-36) of thymopoietin, among the most widely used thymic peptides in clinical practice historically, alongside thymosin and thymosin alpha-1. Research indicates thymosin alpha-1 and thymopentin both increase peripheral blood lymphocyte levels, supporting their shared use as immune-modulating agents in relevant clinical/research contexts.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

No single clinically useful half-life supports a universal schedule; route and immune endpoint matter

Onset

Immune parameter changes studied over days to weeks

Administration Routes (Research)

SC and IV in human clinical studies

Reported Research Effects

Increases peripheral blood lymphocyte levels
Historically among the most widely used thymic peptides in clinical practice

Reported Research Side Effects

No increase in adverse reactions in the 48-week HIV trial
Route-dependent immunostimulation versus immunosuppression has been reported
Historical trials were indication- and co-therapy-specific

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

50 mg SC three times weekly for 48 weeks with zidovudine [SC; Double-blind randomized asymptomatic-HIV trial; Three times weekly]Source: PMID 7859140
50 mg IV over 10 minutes three times weekly for 3 consecutive weeks [IV; Double-blind randomized active-rheumatoid-arthritis study; Three times weekly]Source: PMID 3898298
SC thymopentin on postoperative days 0, 2, and 4 with IV indomethacin days 0-5 [SC plus concomitant IV therapy; Randomized open-heart-surgery immunology study; Three postoperative injections]Source: PMID 1929608; abstract does not state the thymopentin milligram dose

Research Notes

The prior generic statement has been replaced by three distinct tested human protocols. They do not establish a general immune-boosting regimen.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Thymopentin randomized HIV trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/7859140/

Thymopentin randomized rheumatoid-arthritis study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/3898298/

Thymopentin perioperative immunomodulation study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/1929608/

Thymopentin route-dependent immunomodulation in humans — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/6398312/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.